Literature DB >> 23251000

A focus on PD-L1 in human melanoma.

Peter Hersey1, Stuart Gallagher.   

Abstract

Treatment of metastatic melanoma with inhibitors of the BRAF V600 oncogene in melanoma has been limited by the development of resistance. Combining the BRAF inhibitors with immunotherapy may prolong the response, but will acquisition of resistance to BRAF inhibitors also make melanoma cells resistant to immunotherapy?

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23251000     DOI： 10.1158/1078-0432.CCR-12-3312

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  11 in total

1.  Guidelines for biomarker testing in metastatic melanoma: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology.

Authors:  S Martín-Algarra; M T Fernández-Figueras; J A López-Martín; A Santos-Briz; A Arance; M D Lozano; A Berrocal; J J Ríos-Martín; E Espinosa; J L Rodríguez-Peralto
Journal:  Clin Transl Oncol       Date:  2013-10-16       Impact factor: 3.405

2.  Targeting CLEC9A delivers antigen to human CD141+ DC for CD4+ and CD8+T cell recognition.

Authors:  Kirsteen M Tullett; Ingrid M Leal Rojas; Yoshihito Minoda; Peck S Tan; Jian-Guo Zhang; Corey Smith; Rajiv Khanna; Ken Shortman; Irina Caminschi; Mireille H Lahoud; Kristen J Radford
Journal:  JCI Insight       Date:  2016-05-19

3.  RUNX2 is overexpressed in melanoma cells and mediates their migration and invasion.

Authors:  Rajeev K Boregowda; Oyenike O Olabisi; Walid Abushahba; Byeong-Seon Jeong; Keneshia K Haenssen; Wenjin Chen; Marina Chekmareva; Ahmed Lasfar; David J Foran; James S Goydos; Karine A Cohen-Solal
Journal:  Cancer Lett       Date:  2014-03-18       Impact factor: 8.679

4.  The modulation of PD-L1 induced by the oncogenic HBXIP for breast cancer growth.

Authors:  Fei-Fei Xu; Hui-Min Sun; Run-Ping Fang; Lu Zhang; Hui Shi; Xue Wang; Xue-Li Fu; Xian-Meng Li; Xu-He Shi; Yue Wu; Kai Ye; Wei-Ying Zhang; Li-Hong Ye
Journal:  Acta Pharmacol Sin       Date:  2021-04-06       Impact factor: 6.150

Review 5.  Histone Modifications, Modifiers and Readers in Melanoma Resistance to Targeted and Immune Therapy.

Authors:  Stuart J Gallagher; Jessamy C Tiffen; Peter Hersey
Journal:  Cancers (Basel)       Date:  2015-09-25       Impact factor: 6.639

6.  The Major Role of NF-κB in the Depth of Invasion on Acral Melanoma by Decreasing CD8+ T Cells.

Authors:  Hermin Aminah Usman; Bethy S Hernowo; Maringan Diapari Lumban Tobing; Reti Hindritiani
Journal:  J Pathol Transl Med       Date:  2018-04-20

7.  Long Non-coding RNA LINC-PINT Suppresses Cell Proliferation and Migration of Melanoma via Recruiting EZH2.

Authors:  Yangfan Xu; Huixue Wang; Fang Li; Ludwig M Heindl; Xiaoyu He; Jie Yu; Jie Yang; Shengfang Ge; Jing Ruan; Renbing Jia; Xianqun Fan
Journal:  Front Cell Dev Biol       Date:  2019-12-20

8.  Restoration of Peripheral Intermediate and Classical Monocytes Expressing HLA-DR in Patients With Lung Adenocarcinoma After Platinum-Based Chemotherapy.

Authors:  Selma Rivas-Fuentes; Anjarath Higuera Iglesias; Ana García Trejo; Daniel Yair Chavarría Castro; Norma Inclán Figueroa; Teresa Aguirre Pérez; Renata Báez Saldaña; Patricia Gorocica Rosete
Journal:  Technol Cancer Res Treat       Date:  2018-01-01

Review 9.  Harness the synergy between targeted therapy and immunotherapy: what have we learned and where are we headed?

Authors:  Xiaoyan Liu; Qing Zhou; Yan Xu; Minjiang Chen; Jing Zhao; Mengzhao Wang
Journal:  Oncotarget       Date:  2017-09-22

10.  Aspirin-targeted PD-L1 in lung cancer growth inhibition.

Authors:  Yixiang Zhang; Changsheng Lv; Yan Dong; Qingkai Yang
Journal:  Thorac Cancer       Date:  2020-04-15       Impact factor: 3.500
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.